The debate revealed a fundamental gap: whether disease-specific C1q conformational changes or co-localization patterns exist that could enable selective therapeutic targeting. This selectivity problem was identified as 'unsolvable with current technology' but remains critical for complement-based therapies. Source: Debate session sess_sda-2026-04-01-gap-v2-691b42f1 (Analysis: sda-2026-04-01-gap-v2-691b42f1)
Landscape Summary: Can pathological vs physiological C1q tagging be distinguished at the molecular level? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Can pathological vs physiological C1q tagging be distinguished at the molecular level? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: